Genipin crosslinked ethyl cellulose-chitosan complex microspheres for anti-tuberculosis delivery

Colloids and Surfaces B: Biointerfaces

Volumn 103, Issue , 2013, Pages 530-537

  Feng, Hanzhou ^a   Zhang, Limei ^a   Zhu, Chunyan ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Chitosan; Complex microspheres; Ethyl cellulose; Genipin; Intra tracheal intubation; Rifabutin

Indexed keywords

COMPLEX MICROSPHERES; ETHYL CELLULOSE; GENIPIN; INTRA-TRACHEAL INTUBATION; RIFABUTIN;

CHITOSAN; DRUG PRODUCTS; RESPIRATORY THERAPY; SPRAY DRYING; TUBES (COMPONENTS);

MICROSPHERES;

CHITOSAN; ETHYL CELLULOSE; GENIPIN; MICROSPHERE; RIFABUTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; COMPLEX FORMATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSS LINKING; DRUG DOSAGE FORM COMPARISON; DRUG MANUFACTURE; DRUG RETENTION; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; SPRAY DRYING; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL DEATH; CELL LINE, TUMOR; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CROSS-LINKING REAGENTS; DRUG DELIVERY SYSTEMS; HUMANS; IRIDOIDS; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; RIFABUTIN; STATIC ELECTRICITY; VISCOSITY;

RATTUS;

EID: 84871588783     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.11.007     Document Type: Article

References (56)

1. Nahid P., Menzies D. Update in tuberculosis and nontuberculous mycobacterial disease 2011. Am. J. Respir. Crit. Care Med. 2012, 185:1266-1270.
2. Short-course chemotherapy in pulmonary tuberculosis A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1975, 1:119-124.
3. Chukanov V.I., Komissarova O.G., Maishin V., Abdullaev R., Kononets A.S. Efficiency of a new standard chemotherapy regimen in the treatment of patients with recurrent pulmonary tuberculosis. Probl. Tuberk. Bolezn. Legk. 2006, 8:9-13.
4. Kawasaki T., Sasaki Y., Nishimura H., Fujikawa A., Mizuno S., Shimura R., Yamagishi F. A hospital based study on evaluation of causes of death in 52 patients with pulmonary tuberculosis. Kekkaku 2009, 84:667-673.
5. Shafer R.W., Jones W.D. Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid. Tubercle 1991, 72:149-151.
6. Connolly C., Reid A., Davies G., Sturm W., McAdam K.P., Wilkinson D. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 1999, 13:1543-1547.
7. Relapse rate of tuberculosis treated with standard regimen of chemotherapy. Kekkaku 2009, 84:617-625.
8. Haegi V. New aspects of tuberculosis therapy. Schweiz. Med. Wochenschr. 1975, 105:245-250.
9. Visudhiphan P., Chiemchanya S. Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. J. Pediatr. 1989, 114:875-879.
10. Nader L.A., de Mattos A.A., Picon P.D., Bassanesi S.L., De Mattos A.Z., Pineiro Rodriguez M. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?. Ann. Hepatol. 2010, 9:70-74.
11. Gupta P.R., Gupta M.L., Purohit S.D., Sharma T.N., Bhatnagar M. Influence of prior information of drug toxicity on patient compliance. J. Assoc. Physicians India 1992, 40:181-183.
12. Kim A., Krasnova T.K., Romanova V. Use of inhalation of ultrasonic aerosols and galvanic current in the treatment of patients with pulmonary tuberculosis. Ter. Arkh. 1987, 59:96-98.
13. Sharma R., Saxena D., Dwivedi A.K., Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 2001, 18:1405-1410.
14. Hirota K., Hasegawa T., Nakajima T., Inagawa H., Kohchi C., Soma G., Makino K., Terada H. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J. Control. Release 2010, 142:339-346.
15. Sadovnikov A.A. Intrapulmonary instillations in destructive tuberculosis. Grud. Serdechnososudistaia Khir. 1993, 3:40-42.
16. Fu Y., Chu N.H., Yuan S.L., Chen W., Wang W., Luo Y.A., Xiao H.P., Zhu L.Z. The effect of interventional therapy in multimodality treatment on multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 2008, 31:95-98.
17. Purohit S.D., Gupta P.R., Sarkar S.K., Sisodia R.S., Garg A.K. Intracavitary instillation of rifampicin. J. Assoc. Physicians India 1982, 30:480.
18. Beliavskii V.E., Borovinskii A.I. Ways to expand indications for surgical treatment of patients with fibro-cavernous pulmonary tuberculosis. Probl. Tuberk. 1995, 22-25.
19. Furak J., Trojan I., Szoke T., Tiszlavicz L., Morvay Z., Csada E., Balogh A. Surgical intervention for pulmonary tuberculosis: analysis of indications and perioperative data relating to diagnostic and therapeutic resections. Eur. J. Cardiothorac. Surg. 2001, 20:722-727.
20. Snipes M.B., Clem M.F. Retention of microspheres in the rat lung after intratracheal instillation. Environ. Res. 1981, 24:33-41.
21. Mizoe T., Ozeki T., Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech 2008, 9:755-761.
22. Snipes M.B., Chavez G.T., Muggenburg B.A. Disposition of 3-, 7-, and 13-microns microspheres instilled into lungs of dogs. Environ. Res. 1984, 33:333-342.
23. Hu C., Feng H., Zhu C. Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system. Colloids Surf. B Biointerfaces 2012, 95:162-169.
24. Prasertmanakit S., Praphairaksit N., Chiangthong W., Muangsin N. Ethyl cellulose microcapsules for protecting and controlled release of folic acid. AAPS PharmSciTech 2009, 10:1104-1112.
25. Rao K.R., Senapati P., Das M.K. Formulation and in vitro evaluation of ethyl cellulose microspheres containing zidovudine. J. Microencapsul. 2005, 22:863-876.
26. Gao J.Q., Zhao Q.Q., Lv T.F., Shuai W.P., Zhou J., Tang G.P., Liang W.Q., Tabata Y., Hu Y.L. Gene-carried chitosan-linked-PEI induced high gene transfection efficiency with low toxicity and significant tumor-suppressive activity. Int. J. Pharm. 2010, 387:286-294.
27. Lu F., Cao Z., Zhuang Z., Mou Z.X., Feng X. Biodegradation and biocompatibility of a chitosan film. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 1998, 15:183-185.
28. Cheburu C.N., Stoica B., Neamtu A., Vasile C. Biocompatibility testing of chitosan hydrogels. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2011, 115:864-870.
29. Kang Y.M., Lee B.N., Ko J.H., Kim G.H., Kang K.N., Kim da Y., Kim J.H., Park Y.H., Chun H.J., Kim C.H., Kim M.S. In vivo biocompatibility study of electrospun chitosan microfiber for tissue engineering. Int. J. Mol. Sci. 2010, 11:4140-4148.
30. Luz P.P., Nobre T.M., Serra O.A., Zaniquelli M.E. Chitosan as a bioadhesive agent between porphyrins and phospholipids in a biomembrane model. J. Nanosci. Nanotechnol. 2011, 11:1278-1287.
31. Haslam J.L., Egodage K.L., Chen Y., Rajewski R.A., Stella V. Stability of rifabutin in two extemporaneously compounded oral liquids. Am. J. Health Syst. Pharm. 1999, 56:333-336.
32. Kurashima A., Mori T., Tomono Y., Abe S., Nagaoka M., Abe M. A new anti-mycobacterial agent, rifabutin. Kekkaku 2010, 85:743-756.
33. Vostrikov V.V., Selishcheva A.A., Sorokoumova G.M., Shakina Y.N., Shvets V.I., Savel'ev O.Y., Polshakov V.I. Distribution coefficient of rifabutin in liposome/water system as measured by different methods. Eur. J. Pharm. Biopharm. 2008, 68:400-405.
34. Bayne K. Revised Guide for the Care and Use of Laboratory Animals available. American Physiological Society. Physiologist 1996, 39:111-208. 199.
35. Martinac A., Filipović-Grčić J., Voinovich D., Perissutti B., Franceschinis E. Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery. Int. J. Pharm. 2005, 291:69-77.
36. Coowanitwong I., Arya V., Kulvanich P., Hochhaus G. Slow release formulations of inhaled rifampin. AAPS J. 2008, 10:342-348.
37. Yoshida A., Matumoto M., Hshizume H., Oba Y., Tomishige T., Inagawa H., Kohchi C., Hino M., Ito F., Tomoda K., Nakajima T., Makino K., Terada H., Hori H., Soma G. Selective delivery of rifampicin incorporated into poly(dl-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guerin. Microbes Infect. 2006, 8:2484-2491.
38. Tsapis N., Bennett D., O'Driscoll K., Shea K., Lipp M.M., Fu K., Clarke R.W., Deaver D., Yamins D., Wright J., Peloquin C.A., Weitz D.A., Edwards D.A. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis (Edinb.) 2003, 83:379-385.
39. Tomoda K., Ohkoshi T., Nakajima T., Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf. B Biointerfaces 2008, 64:70-76.
40. van den Boogaard J., Kibiki G.S., Kisanga E.R., Boeree M.J., Aarnoutse R.E. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother. 2009, 53:849-862.
41. Kim E.S., Jeong C.S., Moon A. Genipin a constituent of Gardenia jasminoides Ellis, induces apoptosis and inhibits invasion in MDA-MB-231 breast cancer cells. Oncol. Rep. 2012, 27:567-572.
42. Su Y., Mo X. Genipin crosslinked gelatin nanofibers for tissue engineering. J. Control. Release 2011, 152(Suppl. 1):e230-e232.
43. Li M., Liu X. Comparison of characteristics between glutaraldehyde- and genipin-crosslinked gelatin microspheres. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2009, 23:87-91.
44. Yoo J.S., Kim Y.J., Kim S.H., Choi S.H. Study on genipin: a new alternative natural crosslinking agent for fixing heterograft tissue. Korean J. Thorac. Cardiovasc. Surg. 2011, 44:197-207.
45. Xi-xun Y., Fei L., Yuan-ting X., Chang-xiu W. In vitro study in the endothelial cell compatibility and endothelialization of genipin-crosslinked biological tissues for tissue-engineered vascular scaffolds. J. Mater. Sci. Mater. Med. 2010, 21:777-785.
46. Cao Y.Y.H.Z., Pan W.M., Bai X.D., Bi L., Li D., Yang X.B., Liu M. Effect of temperature on crosslinking of collagen/chitosan scaffolds with genipin. Orthop. J. China 2009, 17:217-220.
47. Sangshetti J.N., Hingankar S., Waghule A., Shinde D.B. Stability-indicating (liquid chromatographic) LC method for the determination of rifabutin in bulk drug and in pharmaceutical dosage form. Afr. J. Pharm. Pharmacol. 2011, 5:8.
48. Menon P.R., Lodha R., Singh U., Kabra S.K. A prospective assessment of the role of bronchoscopy and bronchoalveolar lavage in evaluation of children with pulmonary tuberculosis. J. Trop. Pediatr. 2011, 57:363-367.
49. Lasbury M.E., Durant P.J., Lee C.H. Bronchoalveolar lavage fluid from Pneumocystis carinii-infected rats inhibits phagocytosis in normal alveolar macrophages. J. Eukaryot. Microbiol. 2001, (Suppl.):163S-164S.
50. Slusarewicz P., Zhu K., Hedman T. Kinetic analysis of genipin degradation in aqueous solution. Nat. Prod. Commun. 2010, 5:1853-1858.
51. Cao W., Cheng M., Ao Q., Gong Y., Zhao N., Zhang X. Physical, mechanical and degradation properties, and schwann cell affinity of cross-linked chitosan films. J. Biomater. Sci. Polym. Ed. 2005, 16:791-807.
52. Yomota C., Komuro T., Kimura T. Studies on the degradation of chitosan films by lysozyme and release of loaded chemicals. Yakugaku Zasshi 1990, 110:442-448.
53. Emery N., Place G.A., Dodd S., Lhermitte M., David G., Lamblin G., Perini J.M., Page A.M., Hall R.L., Roussel P. Mucous and serous secretions of human bronchial epithelial cells in secondary culture. Am. J. Respir. Cell Mol. Biol. 1995, 12:130-141.
54. Ishizawa K., Suzuki T., Yamaya M., Jia Y.X., Kobayashi S., Ida S., Kubo H., Sekizawa K., Sasaki H. Erythromycin increases bactericidal activity of surface liquid in human airway epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L565-L573.
55. Ventura C.A., Tommasini S., Crupi E., Giannone I., Cardile V., Musumeci T., Puglisi G. Chitosan microspheres for intrapulmonary administration of moxifloxacin: interaction with biomembrane models and in vitro permeation studies. Eur. J. Pharm. Biopharm. 2008, 68:235-244.
56. Schmidt H., Zysk G., Reinert R.R., Bruck W., Stringaris A., Chen V., Stuertz K., Fischer F., Bartels R., Schaper K.J., Weinig S., Nau R. Rifabutin for experimental pneumococcal meningitis. Chemotherapy 1997, 43:264-271.